1. Home
  2. ADVM vs ANEB Comparison

ADVM vs ANEB Comparison

Compare ADVM & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • ANEB
  • Stock Information
  • Founded
  • ADVM 2006
  • ANEB 2020
  • Country
  • ADVM United States
  • ANEB United States
  • Employees
  • ADVM N/A
  • ANEB N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • ANEB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADVM Health Care
  • ANEB Health Care
  • Exchange
  • ADVM Nasdaq
  • ANEB Nasdaq
  • Market Cap
  • ADVM 94.6M
  • ANEB 111.8M
  • IPO Year
  • ADVM 2014
  • ANEB 2021
  • Fundamental
  • Price
  • ADVM $4.32
  • ANEB $2.55
  • Analyst Decision
  • ADVM Buy
  • ANEB Buy
  • Analyst Count
  • ADVM 5
  • ANEB 2
  • Target Price
  • ADVM $16.60
  • ANEB $8.00
  • AVG Volume (30 Days)
  • ADVM 1.0M
  • ANEB 21.6K
  • Earning Date
  • ADVM 11-07-2025
  • ANEB 11-14-2025
  • Dividend Yield
  • ADVM N/A
  • ANEB N/A
  • EPS Growth
  • ADVM N/A
  • ANEB N/A
  • EPS
  • ADVM N/A
  • ANEB N/A
  • Revenue
  • ADVM $1,000,000.00
  • ANEB N/A
  • Revenue This Year
  • ADVM $1,449.40
  • ANEB N/A
  • Revenue Next Year
  • ADVM N/A
  • ANEB N/A
  • P/E Ratio
  • ADVM N/A
  • ANEB N/A
  • Revenue Growth
  • ADVM N/A
  • ANEB N/A
  • 52 Week Low
  • ADVM $1.78
  • ANEB $0.80
  • 52 Week High
  • ADVM $8.18
  • ANEB $3.42
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 50.91
  • ANEB 47.50
  • Support Level
  • ADVM $4.18
  • ANEB $2.51
  • Resistance Level
  • ADVM $4.34
  • ANEB $2.65
  • Average True Range (ATR)
  • ADVM 0.26
  • ANEB 0.11
  • MACD
  • ADVM -0.05
  • ANEB -0.02
  • Stochastic Oscillator
  • ADVM 40.96
  • ANEB 13.51

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About ANEB Anebulo Pharmaceuticals Inc.

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.

Share on Social Networks: